PT  - JOURNAL ARTICLE
AU  - TAKASHI MATSUKI
AU  - CHIHIRO FUSHIMI
AU  - SHUNSUKE MIYAMOTO
AU  - HIDEAKI TAKAHASHI
AU  - TATSUO MASUBUCHI
AU  - YUICHIRO TADA
AU  - KOUKI MIURA
AU  - SHIN-ETSU KAMATA
AU  - KOICHI KANO
AU  - SHOHEI TSUTSUMI
AU  - KAHO MOMIYAMA
AU  - TAKU YAMASHITA
TI  - Preoperative S-1 Therapy for Head and Neck Carcinoma During the Waiting Period Before Surgery
AID  - 10.21873/anticanres.15807
DP  - 2022 Jun 01
TA  - Anticancer Research
PG  - 3177--3183
VI  - 42
IP  - 6
4099  - http://ar.iiarjournals.org/content/42/6/3177.short
4100  - http://ar.iiarjournals.org/content/42/6/3177.full
SO  - Anticancer Res2022 Jun 01; 42
AB  - Background/Aim: In patients with squamous cell carcinoma of the head and neck (SCCHN), delayed surgery can result in poorer postoperative function and prognosis due to the growth of the tumor and extended surgery. Further, delay may even make the tumor unresectable. To prevent tumor growth during the waiting period before surgery, S-1 has been administrated preoperatively at several facilities in Japan. To date, however, the safety and efficacy of preoperative S-1 remain unclear. Patients and Methods: We conducted a retrospective cohort study of 118 patients with SCCHN treated with S-1 before radical surgery at 2 institutions in Japan. We evaluated the safety of S-1 therapy, which was evaluated by the incidence of grade 3 or greater adverse events (AEs). The rate of achievement of non-growth of tumors was also calculated. Results: Regarding safety, 125 AEs of all grades were recorded in 71 patients (60%). Of these, grade 3 AEs were detected in 3 patients (3%), and no grade 4 or 5 AEs occurred. The nongrowth rate of primary lesions and lymph node metastases was 89% and 85%, respectively. Conclusion: Preoperative S-1 therapy might be useful, with acceptable toxicity, on an outpatient basis in patients with SCCHN.